Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Beam Therapeutics announced its Q1 2026 financial results and business updates highlighting promising clinical data from its lead programs including BEAM-302 for alpha-1 antitrypsin deficiency and risto-cel for sickle cell disease. The company expects to initiate pivotal trials and submit regulatory applications by year-end 2026, supported by a str…